Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

伊布替尼 医学 美罗华 弥漫性大B细胞淋巴瘤 来那度胺 内科学 肿瘤科 化疗 化疗方案 淋巴瘤 生发中心 免疫学 B细胞 白血病 多发性骨髓瘤 慢性淋巴细胞白血病 抗体
作者
Jason R. Westin,Loretta J. Nastoupil,Luis Fayad,Fredrick B. Hagemeister,Yasuhiro Oki,Francesco Turturro,Sairah Ahmed,Maria Alma Rodriguez,Hun Ju Lee,Raphael Eric Steiner,Ranjit K. Nair,Simrit Parmar,Ken H. Young,Timothy J. McDonnell,Hubert H. Chuang,Michael R Green,Sattva Swarup Neelapu,Richard Eric Davis
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 1581-1581 被引量:19
标识
DOI:10.1182/blood-2019-128475
摘要

Background: Diffuse Large B-cell Lymphoma (DLBCL), the most common lymphoid cancer, is classified by the cell of origin into the germinal and non-germinal center (non-GCB) subtypes. The non-GCB subtype is associated with inferior outcomes with standard therapies, but the BTK inhibitor ibrutinib (I) and immunomodulatory agent lenalidomide (L) have moderate activity as single agents and result in synthetic lethality when combined in non-GCB DLBCL models (Yang, Cancer Cell 2012). When added to chemotherapy for DLBCL as single agents, neither I nor L have significantly improved outcomes over chemotherapy alone as they only result in synthetic lethality with each other. In relapsed non-GCB DLBCL, a phase Ib trial of rituximab (R), L and I resulted in an overall response rate (ORR) of 65% and median duration of response of 15.9 months (Goy, Blood 2019). Both I and L are also immunomodulatory, shifting from a tumor-mediated immune anergy to an anti-tumor immune response. Methods: We conducted an investigator initiated, open-label, single-arm phase 2 study (Smart Start, NCT02636322) of RLI alone in a 2 cycle lead in followed by RLI combined with standard chemotherapy for 6 cycles in newly diagnosed non-GCB DLBCL patients. Patients were eligible if they had newly diagnosed non-GCB DLBCL (Hans method), adequate organ function and performance status, and were aged 18y or greater. The primary objectives were 1A: to determine the ORR of 2 cycles of RLI, and 1B: to determine the complete response rate (CRR) after RLI-chemotherapy (CHOP or dose adjusted EPOCH per treating MD choice). Therapy consisted of R 375 mg/m2 IV day 1, ibrutinib 560 mg oral daily, and lenalidomide 25 mg oral days 1-10 of a 21 day cycle for 2 cycles, followed by 6 additional cycles of RLI with chemotherapy. All patients were required to receive growth factor support, and prophylaxis for venous thromboembolism and pneumocystis. Responses were determined with PET/CT as per the Lugano criteria. Results: The protocol accrued 60 patients from May 2016 - February 2019, with 58 patients evaluable for disease response (2 withdrew consent prior to restaging). The median age was 63.5 years (range: 29-83), 28% were >= 70 years, and 50% were female. 51.7% had poor risk R-IPI, 65% had advanced stage, 77% had a Ki-67 of >= 80%, and 54% of patients with available tissue were "double expressor" (DE, MYC and BCL2 overexpression via IHC). The median time from diagnosis to therapy was 24 days. The chemotherapy received was CHOP in 43%, (n=25), dose adjusted EPOCH in 55% (n = 32), and none in 2% (n=1). Over 90% of planned ibrutinib and lenalidomide was able to be administered. 13 patients received less than 6 cycles of chemotherapy (C0 = 1, C4 = 4, C5 = 8) due to toxicity, treating physician preference, or patient refusal. Adverse events were generally similar to what is expected with chemotherapy, with the exception of rash in 32% (9% grade 3) and CNS aspergillosis (n = 1). 2 patients suffered grade 5 events (CNS aspergillosis, clostridium difficile colitis). The ORR for 2 cycles of RLI alone was 86% (n=50), the CRR was 36% (n=21), and patients achieving a PR had an 81% median tumor reduction from baseline. The end of therapy ORR is 100% (CR: 95%, PR 5%), with none of the PR patients having relapsed to date without further therapy. The median follow-up at abstract submission is 16 months (1 - 33.5m), with 1 year PFS estimate of 92.5% and OS estimate of 96.5%. Response and survival were not different based upon chemotherapy selected, baseline clinical or pathological variables including DE status or Ki-67%, or number of cycles of therapy received. Correlative studies, including circulating tumor DNA assessment at baseline, after 2 cycles of RLI, and at the end of therapy and beyond are ongoing and will be presented at the meeting. Conclusions: The Smart Start trial demonstrates the combination of rituximab 375 mg/m2 IV, ibrutinib 560 mg oral daily, and lenalidomide 25mg oral d1-10 prior to and with chemotherapy results in impressive response rates and survival in newly diagnosed non-GCB DLBCL compared with historical outcomes. Established adverse prognostic variables including non-GCB, high Ki-67%, and double expression of MYC and BCL2 had similar outcomes with other patients with RLI-based therapy. Further studies are planned to expand the lead-in phase with more targeted agents and number of cycles, and to administer fewer cycles of chemotherapy for patients achieving a CR with a targeted therapy lead-in. Figure Disclosures Westin: Curis: Other: Advisory Board, Research Funding; Celgene: Other: Advisory Board, Research Funding; Janssen: Other: Advisory Board, Research Funding; Novartis: Other: Advisory Board, Research Funding; Genentech: Other: Advisory Board, Research Funding; 47 Inc: Research Funding; Juno: Other: Advisory Board; Unum: Research Funding; MorphoSys: Other: Advisory Board; Kite: Other: Advisory Board, Research Funding. Nastoupil:Bayer: Honoraria; Celgene: Honoraria, Research Funding; Gilead: Honoraria; Janssen: Honoraria, Research Funding; Spectrum: Honoraria; TG Therapeutics: Honoraria, Research Funding; Novartis: Honoraria; Genentech, Inc.: Honoraria, Research Funding. Oki:Jazz: Employment. Parmar:Cellenkos Inc.: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Research Funding. Chuang:Sage Evidence-based Medicine & Practice Institute: Consultancy. Neelapu:Celgene: Consultancy, Research Funding; Unum Therapeutics: Consultancy, Research Funding; BMS: Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Cellectis: Research Funding; Karus: Research Funding; Novartis: Consultancy; Merck: Consultancy, Research Funding; Acerta: Research Funding; Precision Biosciences: Consultancy; Cell Medica: Consultancy; Allogene: Consultancy; Incyte: Consultancy; Poseida: Research Funding; Pfizer: Consultancy. OffLabel Disclosure: Ibrutinib and lenalidomide are not yet indicated for DLBCL, we will describe our trial

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
领导范儿的应助被xia采纳,获得10
3秒前
胖头鱼发布了新的文献求助50
4秒前
Sylvia41完成签到,获得积分10
4秒前
小月月完成签到 ,获得积分10
5秒前
李修名完成签到,获得积分10
5秒前
王中秀完成签到,获得积分10
6秒前
zxz完成签到 ,获得积分10
6秒前
开心谷秋完成签到,获得积分10
6秒前
FFFFFFG完成签到,获得积分10
7秒前
王耑完成签到 ,获得积分10
7秒前
ZC完成签到,获得积分10
7秒前
103x完成签到 ,获得积分10
7秒前
syvshc的应助被蜗牛好好飞采纳,获得10
8秒前
888完成签到 ,获得积分10
9秒前
lii完成签到,获得积分10
9秒前
9秒前
Bi完成签到,获得积分10
10秒前
江清月近人完成签到,获得积分10
11秒前
天晴发布了新的文献求助10
11秒前
12秒前
朴素傲松完成签到,获得积分10
13秒前
郑琦敏钰完成签到 ,获得积分10
13秒前
14秒前
Gobias完成签到,获得积分10
14秒前
jmy完成签到,获得积分10
15秒前
16秒前
小绿完成签到 ,获得积分10
16秒前
石头完成签到,获得积分10
16秒前
Goodenough完成签到,获得积分10
16秒前
TTT完成签到,获得积分10
16秒前
月下思文完成签到 ,获得积分10
16秒前
17秒前
奶酪完成签到 ,获得积分10
17秒前
赖建琛完成签到 ,获得积分0
18秒前
赫里迩斯完成签到,获得积分10
18秒前
xia发布了新的文献求助10
19秒前
大力山蝶完成签到 ,获得积分10
19秒前
阿飞大师完成签到,获得积分10
19秒前
苹果小蜜蜂完成签到,获得积分10
20秒前
无道则愚完成签到 ,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173417
求助须知:如何正确求助?哪些是违规求助? 9565672
关于积分的说明 21781022
捐赠科研通 7767561
什么是DOI,文献DOI怎么找? 3431575
关于科研通互助平台的介绍 2555853
邀请新用户注册赠送积分活动 2476763